Selective Serotonin Reuptake Inhibitors (SSRIs) - Maternal Mental Health
The global selective serotonin reuptake inhibitors (ssris) maternal mental health size was valued at US$ 625.6 million in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 27.5% from 2022 to 2030.
Related Statistics
Selective serotonin reuptake inhibitors (ssris) - Maternal mental health highlights
- The global selective serotonin reuptake inhibitors (ssris) segment generated a revenue of USD 625.6 million in 2022 and is expected to reach USD 4,362.8 million by 2030.
- The market is expected to grow at a CAGR (2023 - 2030) of 27.6% by 2030.
- In terms of region, North America was the largest revenue generating market in 2022.
- Country-wise, China is expected to register the highest CAGR from 2023 to 2030.
Market summary
| Market revenue in 2022 | USD 625.6 million |
| Market revenue in 2030 | USD 4,362.8 million |
| Growth rate | 27.6% (CAGR from 2023 to 2030) |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Maternal Mental Health Scope
Maternal mental health segmentation & scope
Others
Others
Others
Maternal Mental Health
- HTML
- PPT
- -
Everything on Maternal Mental Health in one document: edited and divided into chapters, including detailed references.
Related industry reports
Related Regional Reports
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
